TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline towards Clinical Trials

Thursday, April 04, 2024

Nimble Therapeutics has announced the inauguration of its second R&D facility in Philadelphia, PA. Situated in B+Labs, a renowned center for scientific innovation in University City Philadelphia, this new site signifies a strategic move aimed at advancing Nimble's expanding pipeline of orally-administered peptide therapeutics into clinical development. The Philadelphia hub will synergize with Nimble's primary R&D site in Madison, WI, where the focus lies on leveraging its proprietary platform to optimize oral peptide therapeutics with unmatched scale and speed.

In conjunction with the unveiling of this new site, Nimble has revealed the appointment of two seasoned leaders to spearhead drug discovery efforts and drive the development of the Philadelphia team. Shelley Allen joins as Head of Drug Discovery, entrusted with guiding the advanced optimization and characterization of clinical candidate peptides, shepherding them into clinical trials. Munir Mosaheb assumes the role of Head of Biology, tasked with overseeing the pharmacological, immunological, and translational aspects of Nimble's drug discovery programs.

Shelley brings with her over 25 years of valuable experience in discovering and developing impactful medicines. Previously serving as VP of Medicinal Chemistry at Think Bioscience, and prior to that, contributing significantly to Array Biopharma/Pfizer, she boasts a rich history of nurturing clinical candidates, including notable oncology therapeutics such as Vitrakvi® and Tukysa®. Shelley's journey in medicinal chemistry commenced after completing her undergraduate studies at DeMontfort University of Leicester, and she has since published extensively, amassing over 40 scientific papers and patents.

Munir boasts more than 15 years of expertise in cultivating and applying novel immunological insights across academic and biotech landscapes. Formerly the Head of Translational Biology and Immunology at Senda Biosciences (now Sail Biomedicines), he is credited with building a Translational Biology team and spearheading platform and program development, culminating in IND-enabling preclinical data generation. Munir's academic journey spans diverse aspects of immunology, from molecular vaccinology at Merck & Co. to immuno-oncology and cell trafficking as a post-doctoral fellow in the von Andrian lab at Harvard.

Nimble Therapeutics, expressed delight at the expansion, citing it as a testament to the burgeoning maturity of Nimble's internal pipeline of orally-administered peptide therapeutics and the imperative to bolster capabilities for clinical advancement.

Nimble Therapeutics, extended a warm welcome to Shelley and Munir, recognizing their wealth of experience in pivotal areas of immunology, drug discovery, and preclinical development. He emphasized their pivotal roles in shaping and leading the teams that will usher Nimble's programs into clinical realms.

Shelley conveyed her admiration for the Nimble platform, highlighting its remarkable efficacy and speed in identifying and optimizing oral therapeutic peptides. She expressed eagerness to collaborate with the Madison team in delivering a robust pipeline of clinical candidates to patients.

Munir articulated the significance of Nimble's platform in meeting the growing demand for oral medicines, particularly in immune-mediated diseases. He expressed enthusiasm for contributing to Nimble's vision of pioneering oral peptide therapeutics as next-generation treatments, underscoring the pivotal role he anticipates playing in realizing this vision.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit